{"title":"ESMO 2025 and new therapies in breast cancer: does society always benefit?","authors":"Nabil Ismaili","doi":"10.1080/14737140.2026.2649949","DOIUrl":null,"url":null,"abstract":"<p><p>The ESMO 2025 Congress delivered practice-defining data across breast cancer. Key results included the first overall survival benefit for an adjuvant CDK4/6 inhibitor in high-risk HR+/HER2- early breast cancer and T-DXd established as standard in high-risk HER2+ disease. Novel antibody-drug conjugates redefined first-line therapy for metastatic TNBC. Updated guidelines mandate broader NGS profiling for PALB2, AKT1, and PTEN alterations. A strong emphasis emerged on biomarker-driven de-escalation, strategic sequencing, and proactive endocrine resistance management. However, benefits must be balanced against cost, equity, and the need for academically derived biomarkers. This report summarizes pivotal presentations reshaping clinical decision-making while reflecting on societal impact.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"987-990"},"PeriodicalIF":3.0000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2026.2649949","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The ESMO 2025 Congress delivered practice-defining data across breast cancer. Key results included the first overall survival benefit for an adjuvant CDK4/6 inhibitor in high-risk HR+/HER2- early breast cancer and T-DXd established as standard in high-risk HER2+ disease. Novel antibody-drug conjugates redefined first-line therapy for metastatic TNBC. Updated guidelines mandate broader NGS profiling for PALB2, AKT1, and PTEN alterations. A strong emphasis emerged on biomarker-driven de-escalation, strategic sequencing, and proactive endocrine resistance management. However, benefits must be balanced against cost, equity, and the need for academically derived biomarkers. This report summarizes pivotal presentations reshaping clinical decision-making while reflecting on societal impact.
期刊介绍：
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
